166 results about "Cardiac monitoring" patented technology

Embodiments of the invention provide methods of obtaining continuous cardiac information from a mammal. First, attach a self-contained, wearable, portable continuous cardiac monitor to the mammal to create a chamber containing electrodes used to detect cardiac signals from the mammal. Next, continuously detect without analyzing the cardiac signals from the mammal for at least 24 hours. Next, store information related to substantially all detected cardiac signals in the cardiac monitor.

One embodiment of the invention is a cardiac monitor having a housing; a plurality of electrodes within and extending from the housing; a state machine within the housing configured to digitialize and store in memory signals from the plurality of electrodes; a sealing surface and an adhesive on the sealing surface configured to form a watertight perimeter around the plurality of electrodes when the housing is affixed to a mammal. Another embodiment of the invention provides a continuous cardiac monitor having a housing; a surface on the housing adapted to be sealably engaged to a mammal; an adhesive on the surface that is adapted to remain affixed to the mammal for at least 7 days; at least two electrodes within the housing positioned to detect a cardiac information of the mammal while the surface is sealably engaged to the mammal; an electronic memory within the housing wherein, the electronic memory is sized to store at least 24 hours of continuous cardiac information; and wiring within the housing connecting the electronic memory to the electrodes.

Cardiac monitoring and / or stimulation methods and systems that provide one or more of monitoring, diagnosing, defibrillation, and pacing. Cardiac signal separation is employed for automatic capture verification using cardiac activation sequence information. Devices and methods sense composite cardiac signals using implantable electrodes. A source separation is performed using the composite signals. One or more signal vectors are produced that are associated with all or a portion of one or more cardiac activation sequences based on the source separation. A cardiac response to the pacing pulses is classified using characteristics associated with cardiac signal vectors and the signals associated with the vectors. Further embodiments may involve classifying the cardiac response as capture or non-capture, fusion or intrinsic cardiac activity. The characteristics may include an angle or an angle change of the cardiac signal vectors, such as a predetermined range of angles of the one or more cardiac signal vectors.

Implantable cardiac monitoring and stimulation methods and devices with epicardial leads having sensor feedback. A fixed or extendable / retractable sensor may be displaceable within the lead's lumen and configured to sense the presence of an anatomical feature or physiological parameter of cardiac tissue in proximity with the lead body's distal end. The sensor may include an ultrasonic sensing element, a perfusion sensor, a photoplethysmographic sensor, or a blood oximetry sensor. Methods of determining suitability for implanting a lead involve the steps of accessing an epicardial surface of the heart, and moving the cardiac lead to an implant site at the epicardial surface. A transmitted signal is directed at the implant site. A reflected signal is received, indicative of the presence of a blood vessel at the implant site. A determination may be made to determine whether the implant site is suitable or unsuitable based on the reflected signal.

A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms and otherwise treat heart failure (HF) and pathologies associated with HF. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and / or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with HF (or pathologies associated with HF) and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist, e.g., clonidine, p-aminoclonidine, guanabenz, lidamidine, tizanidine, moxonidine, methyldopa, xylazine, guanfacine, detomidine, medetomidine, and dexmedetomidine.

A retractable multi-use cardiac monitor is provided that includes a memory, and first and second sensing connectors positioned on outsides of first and second housings, respectively. The first and second sensing connectors are configured to detect electrocardiogram (ECG) signals that are stored onto the memory as ECG data. The second housing of the retractable multi-use cardiac monitor also includes a wire retractor configured to extend and retract a wire that connects the second and first housings, and that defines an interelectrode distance between the first and second sensing connectors. The retractable multi-use cardiac monitor further includes systems and methods for determining a length for the interelectrode distance that is optimum in terms of strength and fidelity of the detected ECG signals. The retractable multi-use cardiac monitor further includes a wireless radio configured to transmit a portion of the stored ECG data from the memory to a destination.